238 related articles for article (PubMed ID: 10411585)
1. Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys.
Schneider JS; Tinker JP; Van Velson M; Menzaghi F; Lloyd GK
J Pharmacol Exp Ther; 1999 Aug; 290(2):731-9. PubMed ID: 10411585
[TBL] [Abstract][Full Text] [Related]
2. The subtype-selective nicotinic acetylcholine receptor agonist SIB-1553A improves both attention and memory components of a spatial working memory task in chronic low dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.
Schneider JS; Tinker JP; Menzaghi F; Lloyd GK
J Pharmacol Exp Ther; 2003 Jul; 306(1):401-6. PubMed ID: 12721323
[TBL] [Abstract][Full Text] [Related]
3. Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment.
Schneider JS; Van Velson M; Menzaghi F; Lloyd GK
Ann Neurol; 1998 Mar; 43(3):311-7. PubMed ID: 9506547
[TBL] [Abstract][Full Text] [Related]
4. Attentional cueing reverses deficits in spatial working memory task performance in chronic low dose MPTP-treated monkeys.
Decamp E; Tinker JP; Schneider JS
Behav Brain Res; 2004 Jul; 152(2):259-62. PubMed ID: 15196793
[TBL] [Abstract][Full Text] [Related]
5. Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys.
Schneider JS; Pope-Coleman A; Van Velson M; Menzaghi F; Lloyd GK
Mov Disord; 1998 Jul; 13(4):637-42. PubMed ID: 9686767
[TBL] [Abstract][Full Text] [Related]
6. SIB-1553A, (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride, a subtype-selective ligand for nicotinic acetylcholine receptors with putative cognitive-enhancing properties: effects on working and reference memory performances in aged rodents and nonhuman primates.
Bontempi B; Whelan KT; Risbrough VB; Rao TS; Buccafusco JJ; Lloyd GK; Menzaghi F
J Pharmacol Exp Ther; 2001 Oct; 299(1):297-306. PubMed ID: 11561092
[TBL] [Abstract][Full Text] [Related]
7. Effects of nicotinic therapies on attention and executive functions in chronic low-dose MPTP-treated monkeys.
Decamp E; Schneider JS
Eur J Neurosci; 2006 Oct; 24(7):2098-104. PubMed ID: 17067307
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of (S)-(2)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine HCl (SIB-1508Y, Altinicline), a novel nicotinic acetylcholine receptor agonist.
Rao TS; Adams PB; Correa LD; Santori EM; Sacaan AI; Reid RT; Cosford ND
Brain Res; 2008 Oct; 1234():16-24. PubMed ID: 18692487
[TBL] [Abstract][Full Text] [Related]
9. Profile of nicotinic acetylcholine receptor agonists ABT-594 and A-582941, with differential subtype selectivity, on delayed matching accuracy by young monkeys.
Buccafusco JJ; Terry AV; Decker MW; Gopalakrishnan M
Biochem Pharmacol; 2007 Oct; 74(8):1202-11. PubMed ID: 17706609
[TBL] [Abstract][Full Text] [Related]
10. Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model.
Decamp E; Schneider JS
Brain Res; 2009 Mar; 1262():109-14. PubMed ID: 19368843
[TBL] [Abstract][Full Text] [Related]
11. Effects of the prolyl endopeptidase inhibitor S 17092 on cognitive deficits in chronic low dose MPTP-treated monkeys.
Schneider JS; Giardiniere M; Morain P
Neuropsychopharmacology; 2002 Feb; 26(2):176-82. PubMed ID: 11790513
[TBL] [Abstract][Full Text] [Related]
12. Cognitive enhancing properties and tolerability of cholinergic agents in mice: a comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand for nicotinic acetylcholine receptors.
Bontempi B; Whelan KT; Risbrough VB; Lloyd GK; Menzaghi F
Neuropsychopharmacology; 2003 Jul; 28(7):1235-46. PubMed ID: 12700710
[TBL] [Abstract][Full Text] [Related]
13. Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease.
Parkinson Study Group
Neurology; 2006 Feb; 66(3):408-10. PubMed ID: 16476941
[TBL] [Abstract][Full Text] [Related]
14. Differences in alpha7 nicotinic acetylcholine receptor binding in motor symptomatic and asymptomatic MPTP-treated monkeys.
Kulak JM; Schneider JS
Brain Res; 2004 Mar; 999(2):193-202. PubMed ID: 14759498
[TBL] [Abstract][Full Text] [Related]
15. Long-term cognitive impairment in MPTP-treated rhesus monkeys.
Fernandez-Ruiz J; Doudet DJ; Aigner TG
Neuroreport; 1995 Dec; 7(1):102-4. PubMed ID: 8742427
[TBL] [Abstract][Full Text] [Related]
16. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys.
Decker MW; Bannon AW; Curzon P; Gunther KL; Brioni JD; Holladay MW; Lin NH; Li Y; Daanen JF; Buccafusco JJ; Prendergast MA; Jackson WJ; Arneric SP
J Pharmacol Exp Ther; 1997 Oct; 283(1):247-58. PubMed ID: 9336330
[TBL] [Abstract][Full Text] [Related]
17. Improving effects of huperzine A on spatial working memory in aged monkeys and young adult monkeys with experimental cognitive impairment.
Ye JW; Cai JX; Wang LM; Tang XC
J Pharmacol Exp Ther; 1999 Feb; 288(2):814-9. PubMed ID: 9918593
[TBL] [Abstract][Full Text] [Related]
18. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats.
Menzaghi F; Whelan KT; Risbrough VB; Rao TS; Lloyd GK
J Pharmacol Exp Ther; 1997 Jan; 280(1):393-401. PubMed ID: 8996220
[TBL] [Abstract][Full Text] [Related]
19. Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist, SIB-1508Y, in the learned helplessness rat model of depression.
Ferguson SM; Brodkin JD; Lloyd GK; Menzaghi F
Psychopharmacology (Berl); 2000 Oct; 152(3):295-303. PubMed ID: 11105940
[TBL] [Abstract][Full Text] [Related]
20. Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys.
Quik M; Cox H; Parameswaran N; O'Leary K; Langston JW; Di Monte D
Ann Neurol; 2007 Dec; 62(6):588-96. PubMed ID: 17960553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
